Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANTURA trial of levofloxacin prophylaxis in allogeneic hematopoietic stem cell transplantation
2025-524982-25-00Phase 4Authorised
- Sponsor
- Helsinki University Hospital
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in hematopoietic malignancies, Immunogenetic disorder, primary immune regulatory disorder (PIRD) and 1 more comparing Levofloxacin prophylaxis with Placebo (2 arms). Primary endpoint: Occurrence of at least one bloodstream infection. Planned start Sep 2026; status: authorised.
02
Drugs
levofloxacin
03
Conditions
hematopoietic malignanciesImmunogenetic disorderprimary immune regulatory disorder (PIRD)genetic disorder
Beyond the preview
Go deeper on 2025-524982-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524982-25-00.